Axitinib Oral Tablet [Inlyta]

DRUG2 trials

Sponsors

University of California, San Diego, Centre Leon Berard

Conditions

Clear Cell Renal Cell CarcinomaPapillary Renal Cell Carcinoma Type 2

Phase 2

Prior Axitinib as a Determinant of Outcome of Renal Surgery

Active, not recruitingNCT03438708

University of California, San DiegoClear Cell Renal Cell Carcinoma

Start: 2018-03-05End: 2026-03-04Updated: 2025-10-02

Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

RecruitingNCT05096390

Centre Leon BerardPapillary Renal Cell Carcinoma Type 2

Start: 2022-06-01End: 2026-06-30Target: 72Updated: 2024-01-25

Related Papers

<scp>PADRES</scp> : a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy

British Journal of Urology2023-11-027 citations

Phase II study of axitinib prior to partial nephrectomy to preserve renal function: An interim analysis of the PADRES clinical trial.

Journal of Clinical Oncology2023-02-202 citations

LBA01-08 INTERIM ANALYSIS OF PADRES (PRIOR AXITINIB AS A DETERMINANT OF OUTCOME OF RENAL SURGERY NCT03438708) CLINICAL TRIAL

The Journal of Urology2022-04-07